Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.

Oxular, a UK-based retinal therapeutics developer backed by drug encapsulation company Hovione Scientia and contract pharmaceutical services provider Consort Medical, received $37m in funding yesterday. Venture capital firm Forbion Capital Partners led the round, which also featured investment firm NeoMed, commercialisation firm IP Group and V-Bio Ventures, a venture fund affiliated with life science institute…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.